Steve Lendaris is a full-service life science intellectual property lawyer; assisting clients with strategic patent counseling, post-grant proceedings before the U.S. Patent Trial and Appeal Board (PTAB), and intellectual property litigation. Clients, from universities and small start-ups to large multinational corporations, regularly turn to Steve for advice on a broad range of biotechnology-related issues, from therapeutic antibody development and manufacturing to novel strategies for nucleic acid sequencing. Steve is a frequent lecturer on the use of PTAB proceedings in the life sciences and has spoken extensively on the evolving standard of patent eligibility in the field.
In addition to strategic management of their patent portfolios, clients often retain Steve for assistance with IP diligence matters. Whether it is the review of a competitor's patent portfolio, the purchase of a royalty stream, or the acquisition of an entire enterprise, clients rely on Steve to handle to the deep dives into highly technical areas of science and law in an effort to ensure both IP value and IP risk are appropriately considered.
Steve regularly advises life science companies in connection with post-grant petitions and trials before the PTAB. In addition to conventional ex parte reexamination proceedings, Steve has filed multiple petitions for inter partes review (IPR) on behalf of the firm’s life sciences clients and managed such reviews through to final decisions in the clients' favor. As a member of the firm’s PTAB Trials Committee, Steve regularly reports on developments in the field, focusing particularly on the increased utilization of IPRs by biotechnology and pharmaceutical companies.
Before attending law school, Steve performed his graduate school research on the protein-nucleic acid interactions underlying pre-messenger RNA splicing. Prior to graduate school, he was an assistant process development scientist at a large pharmaceutical company working on the production of recombinant blood clotting factors.
Publications, Speeches and Presentations
- Panelist, “Obtaining Adequate Patent Protection in the U.S.: Factoring Key Cases into Your Biosimilars Patent Strategy,” ACI’s Summit on U.S. Biosimilars, April 2015
- Moderator, “A Toolkit of Practical and Essential IP Advice for Startups,” Joint NYIPLA and Accelerate Long Island IP Program, May 2014
- “The Supreme Court Speaks on Patentability of DNA and ANDA Reverse Payment Settlements,” Baker Botts Seminar, July 2013
- Panelist, “Preparing for the Eventual Employment of the Post Grant Review Procedure in Opposition Practice,” ACI’s Comprehensive Guide to Patent Reform, January 2013
- Moderator, “AIA Implementation: How to Update Your Patent Strategies,” NYIPLA Practice Briefing, September 2012
- “Assessing the Impact of Mayo Collaborative Services v. Prometheus Labs., Inc.,” Baker Botts Seminar, April 2012
- “First-Inventor-to-File & The New Grace Period: Updating IP Strategies in View of the America Invents Act,” C5’s 22nd Forum on Biotech Patenting, March 2012
- “The America Invents Act: Are Secret Uses/Sales Still Prior Art?” ACI’s Comprehensive Guide to Patent Reform for Life Science Companies, January 2012
- “Lessons Learned from Prometheus, Myriad and Classen on Drafting Patent-Eligible Biomarker-Related Claims,” NJIPLA’s 25th Annual Pharmaceutical/Chemical Patent Practice Update, December 2011
- Panelist, “Examining 35 U.S.C. 101 Subject Matter Patentability in the Wake of Myriad and Prometheus,” ACI’s 13th Advanced Forum on Biotech Patents, December 2011
- Panelist, “Are Genes Patentable? Examining the Potential Ramifications of Myriad and Developing Practical Strategies to Protect Your IP,” ACI’s 12th Advanced Forum on Biotech Patents, December 2010
- Panelist, “An Introduction to Gene Patenting: Myriad & Beyond,” the New York City Bar Association’s Science & Law Committee Meeting, May 2010
- Moderator, “Keys to Successful Technology Transfer in the Current Economic Climate,” the Biotechnology Industry Organization’s BIO 2010 International Conference, May 2010
- Panelist, “In re Bilski, Prometheus v Mayo, and ACLU v Myriad: How Current Cases are Impacting the Patent-Eligibility of Biotech Inventions,” the New York Biotechnology Association’s Annual Meeting, April 2010